(2S)-2-amino-N-[(2S)-1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]-1-oxopropan-2-yl]propanamide | 755036-87-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-N-[(2S)-1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]-1-oxopropan-2-yl]propanamide
• CAS: 755036-87-4
• 化学式: C₂₁H₃₁N₅O₃
• 分子量: 401.509
• InChiKey: JIIVQERVTXFCEI-FGRDXJNISA-N

物化性质

• 沸点：
  712.6±60.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2S)-2-amino-N-[(2S)-1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]-1-oxopropan-2-yl]propanamide 、 环己酮 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 72.0h， 以46%的产率得到1-{7-[(6-methoxyquinolin-8-yl)amino]-3-aza-1-methyl-2-oxooc-tyl}-3-methyl-1,4-diazaspiro[4.5]decan-2-one
  参考文献：
  名称：

  在N端带有一个咪唑啉丁-4-酮部分的伯氨喹二肽衍生物作为潜在的抗疟原药

  摘要：

  合成了在N-末端带有咪唑烷基-4-酮部分的伯氨喹二肽衍生物，并将其评估为潜在的阻断传导的抗疟原药。所有化合物均在中性和碱性溶液中水解为伯氨喹的母体二肽衍生物，其半衰期在37°C下为0.7至31 h，具体取决于咪唑烷酮-4-one部分和烷基中存在的取代基的性质。 C端氨基酸直接偶联至伯氨喹。使用由伯氏疟原虫，BalbC小鼠和按蚊按蚊组成的模型研究了所选化合物的抗疟活性蚊子。由丙氨酸-丙氨酸伯氨喹和丙酮衍生的咪唑啉丁-4-酮比伯氨喹更有效地减少了感染向蚊子的传播，这表现为蚊子中肠中的卵囊数量显着减少，分别为10和50μmol/与对照相比，kg。

  DOI：

  10.1016/j.ejmech.2009.01.018
• 作为产物：
  描述：

  磷酸伯氨喹 在 palladium on activated charcoal N-甲基吗啉 、 盐酸 、 氢气 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 (2S)-2-amino-N-[(2S)-1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]-1-oxopropan-2-yl]propanamide
  参考文献：
  名称：

  High Antiplasmodial Activity of Novel Plasmepsins I and II Inhibitors

  摘要：

  The aim of this study was to develop new antiplasmodial compounds acting through distinct mechanisms during both the liver and the blood stages of the parasite life cycle. Compounds were designed on the basis of the "double-drug" approach: primaquine, which has been linked to statine-based inhibitors of plasmepsins (PLMs), the plasmodial aspartic proteases involved in degradation of hemeoglobin. The compounds were tested in vitro for anti-PLM I/PLM II activities and against chloroquine-sensitive (D10) and chloroquine-resistant (W2) strains of P. falciparum. An antiplasmodial activity (IC50) as low as 0.1 mu M was obtained, an excellent improvement in comparison with inhibitors previously reported (IC50 = 2 - 20 mu M). The killing activity was equally directed against both P. falciparum strains and was correlated to lipophilicity (calculated as ALogP), for all compounds but one (9). All compounds inhibited PLM I and PLM II in the nanomolar range (K-i = 1 - 700 nM). The most promising compounds (2, 6, 10) were not cytotoxic against human fibroblasts at 100 mu M and were highly selective for PLMs vs human cathepsin D.

  DOI：

  10.1021/jm061033d

文献信息

• Primaquine dipeptide derivatives bearing an imidazolidin-4-one moiety at the N-terminus as potential antimalarial prodrugs
  作者：Nuno Vale、Fátima Nogueira、Virgílio E. do Rosário、Paula Gomes、Rui Moreira

  DOI：10.1016/j.ejmech.2009.01.018

  日期：2009.6

  Primaquine dipeptide derivatives bearing an imidazolidin-4-one moiety at the N-terminus were synthesized and evaluated as potential transmission-blocking antimalarial prodrugs. All compounds were hydrolyzed to the parent dipeptide derivative of primaquine in neutral and basic solutions, with half lives ranging from 0.7 to 31 h at 37 °C, depending on the nature of the substituents present in the imidazolidin-4-one

  合成了在N-末端带有咪唑烷基-4-酮部分的伯氨喹二肽衍生物，并将其评估为潜在的阻断传导的抗疟原药。所有化合物均在中性和碱性溶液中水解为伯氨喹的母体二肽衍生物，其半衰期在37°C下为0.7至31 h，具体取决于咪唑烷酮-4-one部分和烷基中存在的取代基的性质。 C端氨基酸直接偶联至伯氨喹。使用由伯氏疟原虫，BalbC小鼠和按蚊按蚊组成的模型研究了所选化合物的抗疟活性蚊子。由丙氨酸-丙氨酸伯氨喹和丙酮衍生的咪唑啉丁-4-酮比伯氨喹更有效地减少了感染向蚊子的传播，这表现为蚊子中肠中的卵囊数量显着减少，分别为10和50μmol/与对照相比，kg。
• High Antiplasmodial Activity of Novel Plasmepsins I and II Inhibitors
  作者：Mario Dell'Agli、Silvia Parapini、Germana Galli、Nadia Vaiana、Donatella Taramelli、Anna Sparatore、Peng Liu、Ben M. Dunn、Enrica Bosisio、Sergio Romeo

  DOI：10.1021/jm061033d

  日期：2006.12.1

  The aim of this study was to develop new antiplasmodial compounds acting through distinct mechanisms during both the liver and the blood stages of the parasite life cycle. Compounds were designed on the basis of the "double-drug" approach: primaquine, which has been linked to statine-based inhibitors of plasmepsins (PLMs), the plasmodial aspartic proteases involved in degradation of hemeoglobin. The compounds were tested in vitro for anti-PLM I/PLM II activities and against chloroquine-sensitive (D10) and chloroquine-resistant (W2) strains of P. falciparum. An antiplasmodial activity (IC50) as low as 0.1 mu M was obtained, an excellent improvement in comparison with inhibitors previously reported (IC50 = 2 - 20 mu M). The killing activity was equally directed against both P. falciparum strains and was correlated to lipophilicity (calculated as ALogP), for all compounds but one (9). All compounds inhibited PLM I and PLM II in the nanomolar range (K-i = 1 - 700 nM). The most promising compounds (2, 6, 10) were not cytotoxic against human fibroblasts at 100 mu M and were highly selective for PLMs vs human cathepsin D.